Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

LUN06-116

Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

  • E. M. Casey, W. Harb, D. Bradford, J. Bufill, S. Nattam, J. Patel, W. Fisher, J. E. Latz, J. Wu, N. Hanna. Randomized, Double-Blind, Multicenter, Phase II Study of Pemetrexed (PEM), Carboplatin (CARBO), Bevacizumab (BEV) with Enzastaurin (ENZ) or Placebo (PBO) in Chemo-Naïve Patients with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-116. Accepted to the general poster session (abstract #8035) at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL

Manuscripts/Articles:

  • Casey, Erin M.; Harb, Wael; Bradford, Daniel; Bufill, Jose; Nattam, Sreenivasa; Patel, Jyoti; Fisher, William; Latz, Jane E.; Li, Xiaochun; Wu, Jingwei; Hanna, Nasser. Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116. Journal of Thoracic Oncology. 5(11):1815-1820, November 2010; doi: 10.1097/JTO.0b013e3181ee820c.